Community Practice Connections™: Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease

Activity Overview

This Community Practice Connection™ program provides an in-depth review of some highlights from the 2026 Community Practice Connections™: Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease. This unique and engaging multimedia activity focuses on the practical aspects of managing patients with limited- and extensive-stage small cell lung cancer in the community setting, helping clinicians to gain confidence in using targeted immunotherapies. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.

Target Audience

This educational program is primarily directed toward community-based medical oncologists, radiation oncologists, nurses, nurse practitioners, advanced practice providers, and other health care professionals involved in the treatment of patients with small cell lung cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate consolidation immunotherapy into the management of patients with limited-stage small cell lung cancer (LS-SCLC) who have not progressed after concurrent chemoradiotherapy
• Evaluate the clinical implications of frontline immunotherapy-chemotherapy backbone selection in extensive stage-SCLC
• Develop an evidence-based sequencing strategy for relapsed SCLC based on prior treatment history and disease characteristics

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.